Related references
Note: Only part of the references are listed.The role of immune dysfunction in the pathophysiology of autism
Charity Onore et al.
BRAIN BEHAVIOR AND IMMUNITY (2012)
Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study
Seyed-Hesameddin Abbasi et al.
JOURNAL OF AFFECTIVE DISORDERS (2012)
The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway
Gangadhara Reddy Sareddy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial
Khatereh Sepanjnia et al.
NEUROPSYCHOPHARMACOLOGY (2012)
A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders
Elmira Hasanzadeh et al.
CHILD PSYCHIATRY & HUMAN DEVELOPMENT (2012)
Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome
Paul Ashwood et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation
Hongen Wei et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Transcriptomic analysis of autistic brain reveals convergent molecular pathology
Irina Voineagu et al.
NATURE (2011)
Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia
FuZhou Wang et al.
NEUROSCIENCE RESEARCH (2011)
A Study of Nuclear Transcription Factor-Kappa B in Childhood Autism
Usha S. Naik et al.
PLOS ONE (2011)
Expression Profiling of Autism Candidate Genes during Human Brain Development Implicates Central Immune Signaling Pathways
Mark N. Ziats et al.
PLOS ONE (2011)
Differential monocyte responses to TLR ligands in children with autism spectrum disorders
Amanda M. Enstrom et al.
BRAIN BEHAVIOR AND IMMUNITY (2010)
The immune system's role in the biology of autism
Paula Goines et al.
CURRENT OPINION IN NEUROLOGY (2010)
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results From a Randomized, Double-Blind, Placebo-Controlled Trial
Wijnand Laan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Immune Dysfunction in Autism: A Pathway to Treatment
Milo Careaga et al.
NEUROTHERAPEUTICS (2010)
Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism
Shahin Akhondzadeh et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder
Vala Rezaei et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
Paul H. Patterson
BEHAVIOURAL BRAIN RESEARCH (2009)
Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
R. L. Blaylock et al.
CURRENT MEDICINAL CHEMISTRY (2009)
CLINICAL TRIAL OF ADJUNCTIVE CELECOXIB TREATMENT IN PATIENTS WITH MAJOR DEPRESSION: A DOUBLE BLIND AND PLACEBO CONTROLLED TRIAL
Shahin Akhondzadeh et al.
DEPRESSION AND ANXIETY (2009)
Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism
S. Hossein Fatemi
JOURNAL OF NEUROIMMUNOLOGY (2009)
Reduced Levels of Immunoglobulin in Children With Autism Correlates With Behavioral Symptoms
Luke Heuer et al.
AUTISM RESEARCH (2008)
Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review
Stephane Potvin et al.
BIOLOGICAL PSYCHIATRY (2008)
Low natural killer cell cytotoxic activity in autism: The role of glutathione, IL-2 and IL-15
Aristo Vojdani et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Immune transcriptome alterations in the temporal cortex of subjects with autism
Krassimira Garbett et al.
NEUROBIOLOGY OF DISEASE (2008)
Macrophage migration inhibitory factor and autism spectrum disorders
Elena L. Grigorenko et al.
PEDIATRICS (2008)
S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity
Jing Tian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder
Shahin Akhondzadeh et al.
CHILD PSYCHIATRY & HUMAN DEVELOPMENT (2008)
Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
Shahin Akhondzadeh et al.
SCHIZOPHRENIA RESEARCH (2007)
Effect of pioglitazone treatment on behavioral symptoms in autistic children
Marvin Boris et al.
JOURNAL OF NEUROINFLAMMATION (2007)
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression:: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
N Müller et al.
MOLECULAR PSYCHIATRY (2006)
The immune response in autism: a new frontier for autism research
Paul Ashwood et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Prostaglandin E2 EP1 receptors:: downstream effectors of COX-2 neurotoxicity
T Kawano et al.
NATURE MEDICINE (2006)
Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects
JA Laurence et al.
CEREBELLUM (2005)
Cerebrospinal fluid and serum markers of inflammation in autism
AW Zimmerman et al.
PEDIATRIC NEUROLOGY (2005)
Neuroglial activation and neuroinflammation in the brain of patients with autism
DL Vargas et al.
ANNALS OF NEUROLOGY (2005)
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2
EJ Kim et al.
BRAIN RESEARCH (2002)
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia
N Müller et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression
H Jyonouchi et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus
T Kunz et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Share Paper
